Amgen: Long-Term AI Potential but Limited Near-Term Upside Supports Hold Rating

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Amgen, with a price target of $309.00.

Terence Flynn has given his Hold rating due to a combination of factors tied to Amgen’s evolving but still early AI strategy and its financial risk‑reward profile. Management is aggressively embedding AI across discovery, development, manufacturing, and commercialization, and the company’s vast proprietary datasets and partnership with Nvidia provide a credible foundation for long‑term productivity gains.

However, the discussion with the CTO underscored that these AI initiatives are spread across 10–12 major programs, with benefits accruing gradually and without clear near‑term, quantifiable return targets. While initial examples, such as improved manufacturing efficiency at the new Ohio facility, are encouraging, the payoff remains longer dated, leaving Amgen’s current valuation largely dependent on its existing pipeline and portfolio rather than on immediate AI‑driven upside.

According to TipRanks, Flynn is a 5-star analyst with an average return of 9.8% and a 56.21% success rate. Flynn covers the Healthcare sector, focusing on stocks such as BioNTech SE, Moderna, and Johnson & Johnson.

In another report released yesterday, Cantor Fitzgerald also maintained a Hold rating on the stock with a $350.00 price target.